Dr. Kurt Stoeckli
President and Chief Scientific Officer
“Glenmark is an emerging innovator, capable of rapidly advancing several promising therapies in areas of high unmet medical needs. With a clear and focused strategy as well as promising and proprietary clinical and pre-clinical assets, the mission of our research centers remains steadfast as we are all committed to realizing the full potential of our portfolio. Our culture is science-driven and patient-focused. Our international teams combine personal passion with rigor in science and forward-thinking leadership.”
Dr. Kurt Stoeckli is President and Chief Scientific Officer of Glenmark Pharmaceuticals Ltd., based in Neuchâtel, Switzerland. He oversees global research and early development of innovative products including new biological entities and new chemical entities, with operations in Switzerland, U.S. and India. He also manages both the generics and branded formulations research. Dr. Stoeckli brings more than 25 years of experience in the global life sciences industry where he focused on biopharmaceutical research and development. Prior to joining Glenmark Pharmaceuticals in 2016, Dr. Stoeckli assumed executive roles at SANOFI, first as global therapeutic area head of immunology and inflammation in Germany, and most recently as Group Vice President for the Global Biotherapeutics Division, in Paris. Dr. Stoeckli first joined industry in 1993 with Novartis in Basel, Switzerland where he held increasing leadership positions and provided global support for all biomedical research activities at the Novartis Lead Discovery Center. An immunologist and chemist by training, he graduated from the University of Basel, ETH Zurich and the Max-Planck-Institute for Neurobiology in Munich where he received his Ph.D. in Molecular Cell Biology. Dr. Stoeckli is a Postdoctoral Fellow & Assistant Professor in the Department of Biochemistry & Biophysics, University of California Medical Center.
New Biologic Entity (NBE) Research in Switzerland
Investing in groundbreaking technologies, platforms and facilities ensures that we will continue to drive innovation within our pipeline. In 2006, the Glenmark Biologics Research Centre opened in Neuchâtel, Switzerland. The Swiss research center focuses on the discovery and development of new biological entities comprising GBR 830, an anti-OX40 monoclonal antibody in development to treat atopic dermatitis, as well as other monoclonal antibodies based on Glenmark’s BEAT® [Bispecific Engagement by Antibodies based on the T-cell receptor] platform. Operations in Switzerland include end-to-end capabilities to discover New Biological Entities (NBEs) and develop them from inception through preclinical and clinical studies.
With a world-class, GMP-certified manufacturing line, our Swiss site is well-positioned to fully serve the company’s growth in biologics research and development. The facility provides Glenmark with a full suite of in-house capabilities necessary for early production of investigational biologics medicines, including cell line development, bioassay development and antibody engineering, as well as up- and downstream development.
New Chemical Entity (NCE) Research in India
Located in Mahape, on the outskirts of Mumbai, India, our R&D center has end-to-end capabilities for discovery and development of New Chemical Entities (NCEs), from target selection to clinical development. The 125,000-square-foot research facility is equipped with the state-of-the-art infrastructure required to carry out research activities like medicinal chemistry, process and analytical chemistry, in vitro and in vivo studies, as well as project management.